Document is current
Any future updates will be listed below
-
Authors
Rudofsky, Gottfried https://orcid.org/0000-0002-2576-7190
Menzen, Markus
Potier, Louis
Catarig, Andrei-Mircea
Clark, Alice
Priyadarshini, Prachi
Abreu, Cristina
-
Funding
Funding for this research was provided by:
Novo Nordisk
- License Information
-
More Information
Article History
Received: 25 July 2024
Accepted: 13 September 2024
First Online: 5 December 2024
Declarations
:
: Gottfried Rudofsky has received support, funding, consulting fees and honoraria from Novo Nordisk, and holds stock in Novo Nordisk. Markus Menzen has received consulting fees from Novo Nordisk, Lilly Deutschland, Ascensia, Boehringer Ingelheim, Bayer AG and Novartis; honoraria from AstraZeneca, Bayer AG, Santis, Boehringer Ingelheim, Novo Nordisk, Lilly Deutschland, Lilly Swiss and Abbott; and support for attending meetings from AstraZeneca, Novo Nordisk and Lilly Deutschland. Louis Potier has received research support from Novo Nordisk; consulting fees from Novo Nordisk, Lilly, Sanofi, Bayer, Boehringer Ingelheim and AstraZeneca; and honoraria from Novo Nordisk, Lilly, Sanofi, Bayer and AstraZeneca. Andrei-Mircea Catarig, Alice Clark and Prachi Priyadarshini are full-time employees of Novo Nordisk A/S. Andrei-Mircea Catarig and Prachi Priyadarshini hold stock in Novo Nordisk A/S. Cristina Abreu has no conflicts of interest.
: The SURE study protocols were conducted in accordance with the Declaration of Helsinki and approved by the institutional review board and ethics committee at each participating center. All participants provided written informed consent.
